Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
A human STAT3 gain-of-function variant confers T cell dysregulation without predominant Treg dysfunction in mice
Erica G. Schmitt, Kelsey A. Toth, Samuel I. Risma, Ana Kolicheski, Nermina Saucier, Rafael J. Feliciano Berríos, Zev J. Greenberg, Jennifer W. Leiding, Jack J. Bleesing, Akaluck Thatayatikom, Laura G. Schuettpelz, John R. Edwards, Tiphanie P. Vogel, Megan A. Cooper
Erica G. Schmitt, Kelsey A. Toth, Samuel I. Risma, Ana Kolicheski, Nermina Saucier, Rafael J. Feliciano Berríos, Zev J. Greenberg, Jennifer W. Leiding, Jack J. Bleesing, Akaluck Thatayatikom, Laura G. Schuettpelz, John R. Edwards, Tiphanie P. Vogel, Megan A. Cooper
View: Text | PDF
Research Article Immunology

A human STAT3 gain-of-function variant confers T cell dysregulation without predominant Treg dysfunction in mice

  • Text
  • PDF
Abstract

Primary immune regulatory disorders (PIRD) represent a group of disorders characterized by immune dysregulation, presenting with a wide range of clinical disease, including autoimmunity, autoinflammation, or lymphoproliferation. Autosomal dominant germline gain-of-function (GOF) variants in STAT3 result in a PIRD with a broad clinical spectrum. Studies in patients have documented a decreased frequency of FOXP3+ Tregs and an increased frequency of Th17 cells in some patients with active disease. However, the mechanisms of disease pathogenesis in STAT3 GOF syndrome remain largely unknown, and treatment is challenging. We developed a knock-in mouse model harboring a de novo pathogenic human STAT3 variant (p.G421R) and found these mice developed T cell dysregulation, lymphoproliferation, and CD4+ Th1 cell skewing. Surprisingly, Treg numbers, phenotype, and function remained largely intact; however, mice had a selective deficiency in the generation of iTregs. In parallel, we performed single-cell RNA-Seq on T cells from STAT3 GOF patients. We demonstrate only minor changes in the Treg transcriptional signature and an expanded, effector CD8+ T cell population. Together, these findings suggest that Tregs are not the primary driver of disease and highlight the importance of preclinical models in the study of disease mechanisms in rare PIRD.

Authors

Erica G. Schmitt, Kelsey A. Toth, Samuel I. Risma, Ana Kolicheski, Nermina Saucier, Rafael J. Feliciano Berríos, Zev J. Greenberg, Jennifer W. Leiding, Jack J. Bleesing, Akaluck Thatayatikom, Laura G. Schuettpelz, John R. Edwards, Tiphanie P. Vogel, Megan A. Cooper

×

Figure 6

STAT3 GOF Tregs are functional in vivo.

Options: View larger image (or click on image) Download as PowerPoint
STAT3 GOF Tregs are functional in vivo.
(A) Experimental design for the ...
(A) Experimental design for the Treg treatment studies using the lymphopenia-induced colitis model. (B) Quadratic regression analysis modeling the percent relative weight change over time after the induction of experimental colitis with naive T cells isolated from WT mice. Mice were treated on day 21 with 1 × 106 WT Tregs (n = 24) or G421R Tregs (n = 27), and weight patterns were compared with untreated mice (n = 15) or control C57BL/6 Rag1–/– mice (n = 6). Asterisk represents day 77, at which a significant increase in the weight was observed in colitis mice treated with WT Tregs as compared with untreated mice. (C) Kaplan-Meier survival curves for the mice in B. Comparisons for the survival functions were done using the log-rank test. (D) Percentage of colitogenic Ly5.1+ T cells and Ly5.1– T cells (treatment) isolated from the spleen and MLN of treated mice. (E) Representative flow cytometry from the MLN of treated mice showing Treg recovery. (F) Frequency of transferred Ly5.1– WT or G421R Tregs recovered in the spleen and MLN of treated mice. (G) Frequency of MLN CD3+CD4+Ly5.1+ T cells that produce IFN-γ, both IFN-γ and IL-17A, or just IL-17A after stimulation with PMA/ionomycin. (H) Representative flow cytometry from the MLN of treated mice, demonstrating ex-Treg (CD3+CD4+Ly5.1–EGFP–) cytokine production after restimulation with PMA/ionomycin (left). Scatter plot demonstrating the frequency of MLN ex-Tregs (CD3+CD4+Ly5.1–EGFP–) that produce IL-17A (right). An unpaired t test was used for all comparisons with 2 groups, and Welch’s t test was used in the instance of unequal variance; and for those with 3 or more groups, 1-way ANOVA was used. *P < 0.05, **P < 0.01.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts